Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Dialysis Patients With Type 2 Diabetes: A Real-World Propensity Score–Matched Study

Clicks: 1
ID: 316485
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #110 of 128 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 128 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Aims Patients with type 2 diabetes mellitus (T2DM) undergoing dialysis have extremely high cardiovascular and mortality risks, yet evidence for effective therapies is limited. The benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in this population remain unclear. Methods We conducted a retrospective, propensity score–matched cohort study using the TriNetX US Collaborative Network (2013–2022). Among 1 688 matched pairs of new GLP-1 RA and DPP-4i users, the primary outcome was major adverse cardiovascular events (MACE), with secondary outcomes of all-cause mortality, heart failure, sepsis, hospitalization, and emergency visits. Results GLP-1 RAs users experienced significantly lower risk of MACE compared with DPP-4i users (HR 0.88, 95% CI 0.78–0.99). GLP-1 RAs were also associated with reduced all-cause mortality (HR 0.84, 95% CI 0.72–0.99), myocardial infarction (HR 0.84, 95% CI 0.70–0.99), heart failure (HR 0.87, 95% CI 0.78–0.98), and sepsis (HR 0.81, 95% CI 0.71–0.92). Healthcare utilization outcomes as hospitalization and emergency visits were also reduced. Findings were consistent across sensitivity and subgroup analyses. Conclusions In this large real-world dialysis cohort, GLP-1 RAs were associated with improved cardiovascular outcomes, survival, infection risk, and healthcare utilization, supporting their potential role in T2DM patients receiving dialysis.
Reference Key
openalex_W7163997009 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jia-Jin Chen, Ming‐Hsien Tsai, Wen-Yu Ho, Chieh‐Li Yen, Yu‐Wei Fang, Meng‐Ting Chen, Ching-Chung Hsiao
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag188
URL
https://doi.org/10.1093/ckj/sfag188
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.